Disease Group: Dystonias, NBIA and Paroxysmal Disorders
DBS in Dystonia – the network perspective
Clinical neurophysiology in dystonia
Genetic therapies and therapy developments for rare movement disorders
Dystonic Crisis and Reactions
Strategies of DBS Troubleshooting in Dystonia
Combined and Complex Dystonias
MER and LFP Signals for Implantation and Programming in Dystonia Patients
Neuroimaging for Implantation and Programming in Dystonia Patients
Botulinum Toxin – Opportunities and Limitation
Drug Therapy and Neurorehabilitation – Opportunities and Limitations
Clinical neurophysiology in dystonia
Towards precision medicine in NBIA
Telerehabilitation in RND: an update
DBS in Dystonia – Targets, programming and therapeutic challenges
Basal ganglia diseases in childhood
Deep brain stimulation in children with acquired dystonia
Oligonucleotide therapies: a new class of drugs that allow precise genetic targeting
Functional gait disorders: a sign-based approach
Treatable dystonia &dystonia in inborn errors of metabolism
Gene therapy in neuromuscular and mitochondrial disorders
Myoclonus dystonia
Genetic dystonia and treatment
Functional movement disorders: a diagnostic guide
How can we develop and implement evidence based rehabilitation in rare disorders?
29 Sep. 2020
Speaker: Hortensia Gimeno
Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
How to assess and manage spastic gait in rare diseases
RCT on intrathecal baclofen for dystonia
Goal setting and outcome measures of interventions in pediatric rehabilitation.
18 Jun. 2020
Speaker: Annemieke Buizer
VU University Medical Center Amsterdam, Netherlands;
Emma Children’s Hospital, Amsterdam, Netherlands